Bioverativ

Global biotechnology company dedicated to transforming the lives of people living with hemophilia and other blood disorders.

Launch date

2016

Employees

Market cap

Enterprise valuation

$11.6b (Public information from Jan 2018)

Waltham Massachusetts (HQ)

Revenues, earnings & profits over time

EUR	2016
R&D budget	130m

Source: Dealroom estimates

Date	Investors	Amount	Round
Jan 2017	N/A	N/A	IPO
Jan 2018	Sanofi	$11.6b Valuation: $11.6b	Acquisition
Total Funding		-

Tech stackLearn more about the technologies and tools that this company uses.

ACQUISITION by Bioverativ May 2017

Financials